Recent 8-K filings for VKTX
Highest-materiality recent filing
Viking Therapeutics Reports Q1 2026 Net Loss of $158.3M, Cash of $603M; Phase 3 Obesity Trials Fully Enrolled
- Phase 3 VANQUISH-1 and VANQUISH-2 trials of subcutaneous VK2735 for obesity are fully enrolled; Phase 2 VENTURE study showed up to 14.7% weight loss at 13 weeks.
- Initiation of Phase 3 trial for oral VK2735 expected in 4Q26; Phase 2 VENTURE-Oral showed up to 12.2% weight loss after 13 weeks.
-
Viking Therapeutics annual meeting elects two Class II directors, ratifies auditor
J. Matthew Singleton elected with 28.6M votes for; S. Kathryn Rouan with 22.0M for.
-
Phase 3 VANQUISH-1 and VANQUISH-2 trials of subcutaneous VK2735 for obesity are fully enrolled; Phase 2 VENTURE study showed up to 14.7% weight loss at 13 weeks.
-
Vikings Q4 net loss $157.7M; cash $706M; oral VK2735 Phase 3 to start 3Q26
Full-year 2025 net loss $358.5M ($3.19/sh) vs $110.0M in 2024; R&D spend $345M (up 240% YoY).
-
Viking Therapeutics Reports Q3 2025 Results, Cash $715M, VK2735 Phase 3 Trials On Track
Q3 2025 net loss $90.8M ($0.81/share) vs $24.9M in Q3 2024; R&D expenses rose to $90.0M from $22.8M.
-
VK2735 oral tablet achieves up to 12.2% weight loss in Phase 2 obesity trial
Mean weight loss up to 12.2% (26.6 lbs) from baseline at 13 weeks; placebo-adjusted up to 10.9% (p<0.0001).
-
Viking Therapeutics Q2 net loss $65.6M; Phase 3 VANQUISH obesity trial underway
Net loss $65.6M ($0.58/share) vs $22.3M ($0.20) in Q2 2024; R&D spend $60.2M vs $23.8M.
-
Elected Matthew W. Foehr (28.1M for, 16.2M withheld) and Charles A. Rowland, Jr. (33.0M for, 11.3M withheld) as Class I directors.
-
Viking Therapeutics appoints CBIZ as independent auditor after Marcum resignation
Marcum resigned April 18, 2025, after CBIZ acquired its attest business.
-
Viking Q1 net loss $45.6M ($0.41/sh); cash $852M; VK2735 Phase 3 expected 2Q25
Net loss of $45.6M ($0.41 per share) vs $27.4M ($0.26) in Q1 2024; R&D expense rose to $41.4M.
-
Viking signs $150M manufacturing deal with CordenPharma for VK2735 supply
Viking prepays $150M over 2025-2028 for dedicated API and fill/finish capacity for obesity drug VK2735.
-
Viking Therapeutics reports FY2024 net loss $110M; cash $903M; Phase 3 VK2735 planned 2Q25
Net loss $110.0M ($1.01 per share) for FY2024, compared to net loss $85.9M ($0.91 per share) in 2023.
-
VK2735 oral Phase 1 shows up to 8.2% weight loss; Phase 2 data support monthly maintenance dosing
Oral VK2735 achieved up to 8.2% mean weight loss from baseline (6.8% placebo-adjusted) at 28 days.
-
Viking Therapeutics Q3 net loss $24.9M; cash $930M; pipeline advances with VK2735 and VK2809
Net loss of $24.9M ($0.22 per share) vs $22.5M loss in Q3 2023; R&D expense $22.8M.
-
Viking advances VK2735 to Phase 3 for obesity; Q2 net loss $22.3M
VK2735 to advance to Phase 3 after positive VENTURE study; End-of-Phase 2 meeting with FDA planned for 2H24.
-
NASH resolution with no worsening of fibrosis: 63-75% for VK2809 groups vs 29% placebo (p<0.05 for each, combined p<0.0001).
-
Viking Therapeutics stockholders approve 2024 equity plans and re-elect directors at annual meeting
Stockholders re-elected Brian Lian (50.5M for, 17.4M withheld) and Lawson Macartney (22.3M for, 45.7M withheld) as Class III directors.
-
Viking Q1 net loss $27.4M; VK2735 obesity drug shows up to 14.7% weight loss; cash $963M
Q1 net loss $27.4M ($0.26/sh), R&D expense $24.1M, G&A $10.0M.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.75 · Most common event earnings